Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Oct 15, 2023 11:19am
140 Views
Post# 35684277

RE:RE:RE:RE:RE:Biotech M&A is picking back up according to BiopharmaDive

RE:RE:RE:RE:RE:Biotech M&A is picking back up according to BiopharmaDiveFox it s/b "years". Over the multitude of years this management have never shown they were able to raise the level of enthusiasm to see any meaningful, longlasting sp appreciation. Once again we wait to see whether they can get a deal done and like the past the market, so far, is telling us they aren't very optimistic. I hope I am wrong because like many that have been here for years. I want to see this finally over. This may be their last chance any way because I don't think the market will wait for another 4 years. My first purchase of this stock was between $16 and $17 Cdn. I would be more than happy to get rid of it now for the same.
<< Previous
Bullboard Posts
Next >>